脂肪组织
胰岛素抵抗
产热
脂肪因子
内分泌学
乙酰化
内科学
生物
化学
药理学
肥胖
医学
生物信息学
生物化学
基因
作者
Xin Chu,Cong Cong Zhang,Rui Xin Zhang,Jianfeng Zhang,Bo Xia,Jianli Wu
标识
DOI:10.1016/j.bbadis.2021.166169
摘要
Obesity is a worldwide health problem. Activating fat mobilization and reducing fat synthesis is a promising strategy to mitigate obesity and its complicated metabolic diseases. However, few clinically effective and safe agents conform to the strategy. In the present study, by screening the next-generation L1000-based CMAP small molecule library, we identify histone deacetylase inhibitor Dacinostat, which has been previously tested in clinical trials for patients with advanced solid tumors, as an anti-obesity candidate. Administration of Dacinostat prevents high-fat diet-induced obesity, insulin resistance, and fatty liver in mice without causing adverse effects. Dacinostat treatment enhances adipose thermogenesis as shown by elevated body temperature, accompanied with high mRNA expression of Ucp1 and Ppargc1α. Mechanistically, we show that the thermogenic effect of Dacinostat is achieved by acetylation of histone 3 lysine 27 mediated transcriptional activation of Ucp1 and Ppargc1α in adipose tissue. In conclusion, these findings suggest that Dacinostat is a potential anti-obesity compound through transcriptional activation of adipose thermogenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI